Galen / Barr deal ends uncertainty

Galen Holdings has signed a letter of intent with Barr Laboratories removing the patent risk over three of its four products.

The pharmaceutical company has also agreed to sell the US and Canadian rights for its oral contraceptive product Loestrin.